Current guidelines recommend temozolomide as the first-line chemotherapy for aggressive
pituitary neuroendocrine tumours. However, no clinical trials have been conducted to date …

We evaluated results of temozolomide (TMZ) therapy in six patients, aged 34–78 years,
presenting aggressive pituitary tumors. In all the patients tested O6‐methylguanine‐DNA …

Objective: To collect clinical and treatment outcome data in a large patient cohort, and
specifically to report experience with temozolomide (TMZ). Design: Cohort study based on …

Objectives Only few retrospective studies have reported an efficacy rate of temozolomide
(TMZ) in pituitary tumors (PT), all around 50%. However, the long-term survival of treated …

Background Pituitary tumours are common and easily treated by surgery or medical
treatment in most cases. However, a small subset of pituitary tumours does not respond to …

Temozolomide is effective in some patients with progressive pituitary adenoma or
carcinoma. We report a survey study of Italian patients treated with Temozolomide because …

Context: To date only 18 patients with aggressive pituitary tumors or carcinomas treated with
temozolomide have been reported. Increased expression of O 6-methylguanine-DNA …

Context Despite growing evidence that temozolomide (TMZ) therapy is effective for the
treatment of aggressive pituitary tumors (APTs) or carcinomas (PCs), individual therapy …

Background Treatment of aggressive pituitary adenomas typically involves a multimodality
approach based on histopathological features and may include pharmacotherapy, surgery …

Temozolomide is an oral chemotherapy used to treat aggressive pituitary tumours since
2006. It is inexpensive and well tolerated, the main side effects are fatigue, nausea and …